Compare TG Therapeutics Inc (TGTX) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wayfair Inc — how do they compare? TG Therapeutics Inc trades at $55.24 (market cap $8.16B), while Wayfair Inc trades at $105.86 (market cap $14.40B). The key difference: Wayfair Inc is the larger of the two by market cap, and Wayfair Inc is more actively traded (2,102,856 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Wayfair Inc for 8 Days on average.
| TGTX | W | |
|---|---|---|
Market Cap | $8.16B | $14.40B |
Volume | 1,735,121 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $119.05 |
52-Week Low | $26.94 | $57.40 |
Typical Hold Time | 16 Days | 8 Days |
Enterprise Value | $8.37B | $16.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Wayfair (W) trades at $105.89, up 1.36% with bullish technical signals from moving averages. The company shows revenue growth to $12.9B in 2026 but maintains negative net margins around -2.5%. Recent Q2 2026 earnings beat expectations at $0.95 EPS versus $0.904, while Q3 2026 results are pending. Analyst sentiment is positive with 54% buy ratings and a $114.13 consensus target. The stock faces headwinds from high debt-to-asset ratio of 95.11% and persistent unprofitability despite top-line expansion.
Wayfair presents a mixed outlook with strong revenue growth and technical momentum offset by profitability challenges. The primary opportunity lies in continued market share gains and operational efficiency improvements. Key risks include competitive pressures in e-commerce, high leverage, and macroeconomic sensitivity. Investors should weigh the bullish analyst consensus against fundamental weaknesses in margin performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
